Abbott Laboratories (NYSE:ABT) Plans $0.63 Quarterly Dividend

Abbott Laboratories (NYSE:ABT) announced a quarterly dividend on Thursday, September 17th. Stockholders of record on Thursday, October 15th will be paid a dividend of 0.63 per share by the healthcare product maker on Monday, November 16th. This represents a c) dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th.

Abbott Laboratories has increased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 54 years. Abbott Laboratories has a dividend payout ratio of 44.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Abbott Laboratories to earn $6.08 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $102.20 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market cap of $176.84 billion, a P/E ratio of 33.07, a PEG ratio of 1.90 and a beta of 0.59. The business’s 50-day moving average price is $106.18 and its two-hundred day moving average price is $99.38.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.